Bharat Parenterals Peer Comparison

BSE: 541096

₹1,527.80

₹31.20 (2.08%)

As on 28-Aug-2026IST

Market cap

₹1,060 Cr

Revenue (TTM)

₹323 Cr

P/E Ratio

P/B Ratio

3.3

Div. Yield

0.1 %

Edit

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	1,060	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	323	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	-29.99	735.15	678.07	666.92	169.62
Net Margin (%)	-9.01	26.88	28.10	20.60	6.90
RoE (%)	-4.72	19.16	19.73	18.75	20.76
Price to Earnings	--	29.25	28.74	28.35	104.74
Price-To-Book	3.33	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	323.17	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	332.76	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	312.59	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	10.58	941.63	796.58	1,139.61	229.86
Depreciation	34.33	57.58	78.10	281.06	17.24
EBIT	-23.75	884.05	718.48	858.55	212.62
Interest	11.31	7.69	0.88	190.64	5.72
Other Income	9.60	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	-25.46	992.82	843.56	658.12	228.25
Provision for Tax	4.53	257.67	165.49	-8.80	58.63
Profit after Tax	-29.99	735.15	678.07	666.92	169.62

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	322.23	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	14.59	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	144.32	91.50	28.74	1,392.75	134.50
Current Liabilities	157.39	627.48	385.94	2,077.10	981.81
Total Liabilities	658.37	4,911.11	3,207.85	6,862.28	1,879.19

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	293.10	770.28	1,291.22	5,617.77	42.47
Current Assets	310.08	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	658.37	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	180.20	2.50	0.55	2,421.66	0.00
Net Current Assets	152.69	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	50.91	363.79	0.64	64.29	98.41

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	-27.25	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	-137.38	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	156.37	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	-8.27	383.07	59.32	103.72	30.57

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	-4.85	26.21	26.22	13.59	21.29
ROE (%)	-4.72	19.16	19.73	18.75	20.76
ROA (%)	-4.75	14.95	18.69	9.26	9.67
EBIT Margin (%)	-7.35	34.40	31.41	26.58	8.74
Net Margin (%)	-9.01	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	-11.19	10.69	15.01	9.59	31.10
EBIT Growth (%)	-3.75	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	15.99	-9.09	19.61	62.68	-7.49
EPS Growth (%)	-152.62	14.40	17.73	67.41	-18.33
Book Value Growth (%)	67.63	17.30	23.77	10.19	7.70

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	-68.84	27.87	28.74	27.66	102.37
Price / Book Value	3.33	4.88	5.08	4.51	19.65
Dividend Yield (%)	0.07	1.60	0.16	0.55	0.51
EV/EBITDA	111.32	19.53	22.88	17.94	75.34
Market Cap (₹ Cr)	680.56	18,318.10	15,219.80	19,292.77	21,515.93

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.38	0.00	0.00	0.24	0.00
Short term debt to equity ratio	0.30	0.00	0.00	0.14	--
Current Ratio	1.97	6.06	6.70	0.74	1.77
Quick Ratio	1.43	5.31	5.59	0.53	0.73
Interest Coverage	-1.25	130.11	959.59	4.45	40.90

	Bharat Parenterals	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	46.62	7.07	36.10	21.07	8.79
Asset Turnover	0.51	0.52	0.63	0.45	1.39
Receivable days	167.45	29.10	110.70	54.07	35.81
Inventory Days	71.34	69.53	65.86	32.16	82.25
Payable days	131.49	76.77	105.88	140.91	124.39
Cash Conversion Cycle	107.30	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.